Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Authors Hager K, Baseman A, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards H
Received 22 July 2014
Accepted for publication 22 July 2014
Published 20 October 2014 Volume 2014:10 Pages 1997—1998
Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. Neuropsychiatr Dis Trea. 2014;10:391–401.
On page 393, Figure 1, “Maintenance period (month 6 to 24)” should be “Maintenance period (month 4 to 24)”; “– Gal at stable dose (at least 18 mg/day) as achieved on day 84c” should be “– Gal at stable dose (at least 16 mg/day) as achieved on day 84c”.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]